[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surgical-bleeding\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surgical-bleeding":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100656758","phase-3-absorbable-hemostatic-fluid-gelatin-trial-100656758",false,"NCT07830797","Absorbable Hemostatic Fluid Gelatin Trial","A Multicenter, Single-Blind, Randomized Controlled Clinical Trial of the Safety and Efficacy of Absorbable Hemostatic Fluid Gelatin for Surgical Hemostasis","Inclusion Criteria:\n\n* 1\\. Age ≥18 years;\n* 2\\. Scheduled for elective\u002Fsemi-elective surgery in General Surgery, Orthopedics, or Gynecology;\n* 3\\. Signed informed consent. (Intra-op): 1. Presence of a suitable Target Bleeding Site (TBS).\n\nExclusion Criteria:\n\n* 1\\. Allergy to porcine gelatin or refusal of porcine-derived products;\n* 2\\. INR\\>1.5 or PLT\\\u003C100×10⁹\u002FL;\n* 3\\. Severe hepatic\u002Frenal dysfunction;\n* 4\\. Pregnancy\u002Flactation;\n* 5\\. Participation in another trial within 30 days;\n* 6\\. Unsuitable per investigator.","ALL","18 Years",{"count":19,"type":20},324,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This is a multicenter, single-blind, randomized controlled, non-inferiority trial evaluating the safety and efficacy of an absorbable hemostatic fluid gelatin for surgical hemostasis. Subjects are patients undergoing elective\u002Fsemi-elective surgeries in General Surgery, Orthopedics, and Gynecology. The test group receives the investigational device, while the control group receives a marketed predicate device (SURGIFLO). The primary outcome is the 5-minute hemostasis success rate at the Target Bleeding Site (TBS).",[26],"Surgical Bleeding",[28,29,30,31],"Hemostasis","Absorbable Gelatin","Fluid Gelatin","Surgical Hemostasis","NOT_YET_RECRUITING","2026-09-15",{"date":35,"type":36},"2026-09-21","ACTUAL",{"date":38,"type":20},"2026-09-08",{"date":40,"type":20},"2027-08-31",{"name":42,"class":43},"Medprin Regenerative Medical Technologies Co., Ltd.","INDUSTRY"]